natgillin/translations-raw huggingface dataset:
Hos cynomolgus aber blev der bemærket systolisk hjertemislyd uden makroskopiske eller mikroskopiske korrelater hos individuelle dyr, der blev behandlet med 5 og 45 mg/kg i toksicitetsstudiet med enkeltdosis og med 1, 2,5 og 5 mg/kg i 4-ugers toksicitetsstudiet med gentagen dosering.
In cynomolgus monkeys, systolic heart murmurs with no macroscopic or microscopic correlates were noted in individual animals treated with 5 and 45 mg/kg in the single dose toxicity study and at 1, 2.5 and 5 mg/kg in the 4-week repeat-dose toxicity study.
Hos cytopeniske hunde var der ingen bivirkninger p å stamceller og prolifererende celler i knoglemarven.
In cytopenic dogs, there were no adverse events on progenitor and proliferating cells in the bone marrow.
Hos dasatinib- behandlede patienter var de observerede mutationer T315I, F317I/L og V299L.
The mutations detected among the dasatinib-treated patients were T315I, F317I/L and V299L.
Hos de 128 patienter, hvor nivolumab i kombination med ipilimumab blev seponeret på grund af bivirkninger, var median-PFS 16,7 måneder (95% CI: 10,2; NA) og ORR 69% (88/128), hvoraf 15% (19/128) opnåede komplet respons.
Among 128 patients who discontinued nivolumab in combination with ipilimumab due to adverse reaction, median PFS was 16.7 months (95% CI: 10.2, NA), and the ORR was 69% (88/128) with 15% (19/128) achieving a complete response.
Hos de 16 patienter med MCD, der fik 11 mg/kg hver 3. uge, var den samlede tumorresponsrate ifølge en uvildig gennemgang 43,8 % med 6,3 % komplet respons.
In the 16 patients with MCD treated with 11 mg/kg every 3 weeks, overall tumour response rate by independent review was 43.8% with 6.3% complete response.
Hos de 20 patienter, som ikke havde nogen af disse risikofaktorer, sås ingen udvikling af inhibitorer.
In the 20 subjects who had none of these risk factors there was no inhibitor development.
Hos de 22 patienter under 2 år, som blev behandlet med voriconazol i et compassionate use-program, er følgende bivirkninger (for hvilke en sammenhæng med voriconazol ikke kan udelukkes) rapporteret: Lysoverfølsomheds reaktioner (1), arytmi (1), pancreatitis (1), forhøjet serum-bilirubin (1), forhøjet antal leverenzymer (1), udslæt (1) og papilødem (1).
In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1).
Hos de 22 patienter under 2 år, som blev behandlet med voriconazol i et compassionate use-program, er følgende bivirkninger (for hvilke en sammenhæng med voriconazol ikke kan udelukkes) rapporteret: Lysoverfølsomheds- reaktioner (1), arytmi (1), pancreatitis (1), forhøjet serum-bilirubin (1), forhøjet antal leverenzymer (1), udslæt (1) og papilødem (1).
In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1).
Hos de 22 patienter under 2 år, som blev behandlet med voriconazol i et ”compassionate use” program, er følgende bivirkninger (for hvilke en sammenhæng med voriconazol ikke kan udelukkes) rapporteret: Lysoverfølsomhedsreaktioner (1), arytmi (1), pancreatitis (1), forhøjet serum-bilirubin (1), forhøjet antal leverenzymer (1), udslæt (1) og papilødem (1).
In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1).
Hos de 800 randomiserede patienter var medianalderen 63 år, 61% var mænd, 58% var kaukasere/hvide, 35% var asiater/orientalske, og 1% var sorte/afrikansk-amerikanere, og alle patienter havde Eastern Cooperative Oncology Group (ECOG) performance status (PS) på 0 eller 1 ved baseline.
Of the 800 randomised patients, the median age was 63 years, 61% were male, 58% were Caucasian/White, 35% were Asian/Oriental, and 1% were Black/African American, and all patients had baseline Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
Hos de behandlingserfarne patienter var Isentress mere effektivt end placebo: 77 % af de patienter, som fik Isentress, havde en virusbelastning på under 400 kopier/ml efter 16 uger, sammenlignet med 42 % af dem, der havde fået placebo.
In treatment-experienced patients, Isentress was more effective than placebo: 77% of the patients who took Isentress had viral loads below 400 copies/ml after 16 weeks, compared with 42% of those who took placebo.
Hos de behandlingsnaive mRCC-patienter, der fik IFN-α, forekom 6 (2%) tromboemboliske hændelser; 1 patient (<1%) oplevede en grad 3 DVT, og 5 patienter (1%) fik lungeemboli, alle grad 4.
In treatment-naïve MRCC patients receiving IFN-, six (2%) venous thromboembolic events occurred; one patient (<1%) experienced a Grade 3 DVT and five patients (1%) had pulmonary embolisms, all with Grade 4.
Hos de CKD-patienter, der var i dialyse, og som indtog cinacalcett, havde cirka 30% af patienterne mindst én serumcalciumværdi på under 7,5 mg/dl (1,9 mmol/l).
In Chronic Kidney Disease (CKD) patients receiving dialysis who were administered cinacalcet, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
Hos de CKD-patienter, der var i dialyse, og som indtog Mimpara, havde cirka 30 % af patienterne mindst én serumcalciumværdi på under 7,5 mg/dl (1,9 mmol/l).
In CKD patients receiving dialysis who were administered Mimpara, approximately 30% of patients had at least one serum calcium value less than 7.5 mg/dl (1.9 mmol/l).
Hos de fleste mennesker er der ingen tegn på kolesterol- eller triglyceridproblemer til at begynde med.
In most people, there are no signs of cholesterol or triglycerides problems at first.
Hos de fleste mennesker er der ingen tegn på kolesterolproblemer til at begynde med.
In most people, there are no signs of cholesterol problems at first.
Hos de fleste mennesker med depression eller angst begynder Cymbalta at virke indenfor de første to uger, men det kan vare 2-4 uger, før du får det bedre.
Cymbalta starts to work in most people with depression or anxiety within two weeks of starting treatment, but it may take 2-4 weeks before you feel better.
Hos de fleste mennesker med depression eller angst begynder Duloxetin Lilly at virke indenfor de første to uger, men det kan vare 2-4 uger, før du får det bedre.
Duloxetine Lilly starts to work in most people with depression or anxiety within two weeks of starting treatment, but it may take 2-4 weeks before you feel better.
Hos de fleste mennesker med depression eller angst begynder Xeristar at virke indenfor de første to uger, men det kan vare 2-4 uger, før du får det bedre.
Xeristar starts to work in most people with depression or anxiety within two weeks of starting treatment, but it may take 2-4 weeks before you feel better.
Hos de fleste patienter kunne infliximab påvises i serum i mindst 8 uger efter den anbefalede enkeltdosis på 5 mg/kg til Crohns sygdom og reumatoid arthritis vedligeholdelsesdosis på 3 mg/kg hver 8. uge.
In most patients, infliximab could be detected in the serum for at least 8 weeks after the recommended single dose of 5 mg/kg for Crohn’s disease and the rheumatoid arthritis maintenance dose of 3 mg/kg every 8 weeks.
Hos de fleste patienter kunne perflutren ikke spores i blodet eller ekspirationsluften efter 4-5 minutter.
In most subjects after 4-5 minutes, perflutren was undetectable in blood and expired air.
Hos de fleste patienter med alvorlig hyperkalcæmi (albuminkorrigeret serum-calcium* ≥3 mmol/l eller
In most patients with severe hypercalcaemia (albumin-corrected serum calcium
Hos de fleste patienter med svær hyperkalcæmi (albuminkorrigeret serum-calcium* ≥3 mmol/l eller ≥12 mg/dl) er 4 mg en passende enkelt-dosis.
In most patients with severe hypercalcaemia (albumin-corrected serum calcium* ≥3 mmol/l or ≥12 mg/dl) 4 mg is an adequate single dose.
Hos de fleste patienter med svær hyperkalcæmi (albuminkorrigeret serum-calcium*  3 mmol/l eller  12 mg/dl) vil 4 mg være en passende enkelt dosis.
In most patients with severe hypercalcaemia (albumin-corrected serum calcium* ≥3 mmol/l or ≥12 mg/dl) 4 mg is an adequate single dose.
Hos de fleste patienter med svær hyperkalcæmi (albuminkorrigeret serum-calcium*  3 mmol/l eller  12 mg/dl) vil 4 mg være en passende enkelt dosis.
In most patients with severe hypercalcaemia (albumin-corrected serum calcium* 3 mmol/l or 12 mg/dl) 4 mg is an adequate single dose.
Hos de fleste patienter med svær hyperkalcæmi (albuminkorrigeret serum-calcium*  3 mmol/l eller  12 mg/dl) vil 4 mg være en passende enkelt-dosis.
In most patients with severe hypercalcaemia (albumin-corrected serum calcium* 3 mmol/l or 12 mg/dl) 4 mg is an adequate single dose.
Hos de fleste patienter var smerten forbundet med patientens underliggende cancer, metastaser, tidligere sygdomme eller samtidige sygdomme.
In the majority of patients the pain was related to the patients’ underlying cancer or metastases or pre-existing or concomitant conditions.
Hos de ikke tidligere hivbehandlede patienter var Isentress lige så effektivt som efavirenz.
In patients who had not taken HIV treatment before, Isentress was as effective as efavirenz.
Hos de kvinder, der fik en højere dosis, gik der gennemsnitligt 6,5 måneder, uden at sygdommen blev værre, sammenlignet med 5,5 måneder hos dem, der fik en lavere dosis.
250-mg dose: the women receiving the higher dose lived for an average of 6.5 months without their disease getting worse, compared with 5.5 months in those receiving the lower dose.
Hos de novo nyre- og levertransplanterede patienter var AUC0-24 af tacrolimus for Advagraf på dag 1 henholdsvis 30 % og 50 % lavere, når den blev sammenlignet med en tilsvarende dosis af den umiddelbart udløste kapsel (Prograf).
In de novo kidney and liver transplant patients AUC0-24 of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for the immediate release capsules (Prograf at equivalent doses.
Hos de patienter i TRA 2°P - TIMI 50-studiet (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events), der blev behandlet med vorapaxar, herunder patienter med apopleksi i anamnesen, blev der observeret en højere hyppighed af intrakraniel blødning (ICH) hos de patienter, der vejede <60 kg i forhold til de patienter, der vejede ≥60 kg.
In TRA 2°P - TIMI 50, in vorapaxar- treated patients, including those with history of stroke, a higher rate of ICH was observed in patients weighing <60 kg compared to patients weighing ≥60 kg.
Hos de patienter med AP og BP CML, der tidligere var blevet behandlet med mindst en TKI (imatinib), var effektmålene det kumulative totale hæmatologiske respons (OHR) og tid til og varighed af OHR.
For patients with AP and BP CML previously treated with at least one prior TKI (imatinib), the endpoints were cumulative overall haematologic response (OHR) and time to and duration of OHR.
Hos de patienter som bliver neutropeniske (ANC < 1,5 x 109/l) bør ANC kontrolleres tæt og behandling med Kineret seponeres.
In patients who become neutropenic (ANC < 1.5 x 109/l) the ANC should be monitored closely and Kineret treatment should be discontinued.
Hos de patienter, der allerede får en optimeret vardenafildosis, bør behandling med alfa-blokker initieres med den laveste dosis.
In those patients already taking an optimised dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose.
Hos de patienter, der blev behandlet med infliximab, og som fik mindst en kort infusion, opstod infusionsrelaterede reaktioner hos 15 % af patienterne, og alvorlige infusionsreaktioner opstod hos 0,4 % af patienterne.
Of the infliximab- treated patients who received at least one shortened infusion, infusion-related reactions occurred in 15% of patients and serious infusion reactions occurred in 0.4% of patients.
Hos de patienter, der er i stabil alfa-blokker- behandling, bør vardenafil initieres med den laveste anbefalede startdosis på 5 mg filmovertrukne tabletter.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg film-coated tablets.
Hos de patienter, der er i stabil alfa-blokker-behandling, bør vardenafil initieres med den laveste anbefalede startdosis på 5 mg.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5 mg.
Hos de patienter, der er i stabil alfa-blokker-behandling, bør vardenafil initieres med den laveste anbefalede startdosis på 5 mg.
In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5mg.
Hos de patienter, der fik 15 mikrogram, var den tilsvarende andel 85 %.
The figure was 85% in the patients who received the 15-microgram dose.
Hos de patienter, der fik Cerdelga, var der desuden bedring i andre sygdomstegn, såsom reduktion i størrelsen af leveren og stigning i hæmoglobin (det protein i de røde blodlegemer, der transporterer ilt i kroppen).
Patients who received Cerdelga also showed an improvement of other signs of the disease such as a reduction in liver size and increased levels of haemoglobin (the protein found in red blood cells that carries oxygen around the body).
Hos de patienter, der fik Forxiga, var der en lille forøgelse i antallet af tilfælde af blære-, bryst- og blærehalskirtelkræft i forhold til dem, der fik placebo.
A small but higher number of bladder, breast and prostate cancer cases were seen in patients who took Forxiga compared with patients who took placebo.
Hos de patienter, der fik insulin uden pioglitazon, var incidensen af hjertesvigt 8,2 % hos patienter ≥65 år og 4,0 % hos patienter under 65 år.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥ 65 years compared to 4.0% in patients less than 65 years.
Hos de patienter, der fik insulin uden pioglitazon, var incidensen af hjertesvigt 8,2 % hos patienter ≥65 år og 4,0 % hos patienter under 65 år.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥65 years compared to 4.0% in patients less than 65 years.
Hos de patienter, der fik pioglitazon og insulin i dette studie, var procentdelen af patienter med hjertesvigt højere hos patienterne ≥ 65 år end hos patienterne under 65 år (9,7 % sammenlignet med 4,0 %).
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged >65 years compared with those less than 65 years (9.7% compared to 4.0%).
Hos de patienter, der fik placebo, var den tilsvarende andel 15 %.
This compares with 15% of patients on placebo.
Hos de patienter, der fik Raplixa, standsede blødningen inden for 1-2 minutter, sammenholdt med 2-4 minutter hos patienterne i kontrolgruppen.
Across all surgery types, patients in the Raplixa group had their bleeding stopped within 1 to 2 minutes compared with 2 to 4 minutes for patients in the control group.
Hos de patienter, der fik Relvar Ellipta, var der mellem 13 og 34 % færre anfald med forværring af KOL end hos dem, der fik vilanterol alene.
COPD flare-ups were reduced by between 13 and 34% in those using Relvar Ellipta compared with vilanterol alone.
Hos de patienter, der fik Revinty Ellipta, var der mellem 13 og 34 % færre anfald med forværring af KOL end hos dem, der fik vilanterol alene.
COPD flare-ups were reduced by between 13 and 34% in those using Revinty Ellipta compared with vilanterol alone.
Hos de patienter, der fik Xeloda og cisplatin, gik der 5,6 måneder, uden at sygdommen skred frem, mens der gik 5,0 måneder hos dem, der fik 5-FU og cisplatin.
It took 5.6 months for the disease to get worse in patients taking Xeloda and cisplatin, and 5.0 months in patients receiving 5-FU and cisplatin.
Hos de patienter, der gennemgik en knæoperation, var de tilsvarende tal 15 % (147 ud af 976) for Eliquis sammenlignet med 24 % (243 ud af 997) for enoxaparin.
In patients undergoing a knee replacement, the corresponding numbers were 15% (147 out of 976) for Eliquis compared with 24% (243 out of 997) for enoxaparin.
Hos de patienter, der ikke fik samtidig PAH- specifik behandling, var den placebokorrigerede behandlingsvirkning målt ved laveste koncentration 34 m (99 % CI: 10, 63 m).
In patients without concurrent PAH-specific therapy, the placebo-corrected treatment effect measured at trough was 34 m (99% CI: 10, 63 m).
Hos de patienter, der oprindeligt fik infliximab og derefter skiftede til abatacept, var reduktionen i den gennemsnitlige DAS28-score fra baseline 3,29 på dag 729 og 2,48 på dag 365.
In those patients who initially received infliximab and then switched to abatacept, the reduction in the mean DAS28 score from baseline were 3.29 at day 729 and 2.48 at day 365.
Hos de patienter, der rapporterdeforhøjet ALAT eller ASAT (alle grader) i studiet, var mediantid til indtræden 28 dage med et interval på 6 til 841 dage for ALAT og på 1 til 680 dage for ASAT.
Among patients with reports of adverse reactions of elevations in either ALT or AST (all grades), the median time of onset observed in the study was 28 days with a range of onset 6 to 841 days for ALT and 1 to 680 days for AST.
Hos de patienter, der tidligere var blevet behandlet med imatinib og mindst en yderligere TKI, omfattede effektmålene den kumulative MCyR-rate, tid til og varighed af MCyR og tid til og varighed af CHR.
For patients previously treated with both imatinib and at least 1 additional TKI, the endpoints include the cumulative MCyR rate, time to and duration of MCyR, and time to and duration of CHR.
Hos de patienter, der var refraktære for lenalidomid (25 %), var median-PFS 8,6 måneder i Kd-armen vs.
In patients refractory to lenalidomide (25%), median PFS was 8.6 months in the Kd arm versus
Hos de patienter, hvor det er nødvendigt at bruge den samme i.v. adgang, skal denne (inklusive Y- slangen) skylles grundigt med en 0,9 % natriumchlorid opløsning eller 5 % glucose opløsning før og efter Rapilysin injektionen.
In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with 0.9 % sodium chloride or 5 % glucose solution prior to and following the Rapilysin injection.
Hos de patienter, hvor det er nødvendigt at bruge den samme i.v. adgang, skal denne (inklusive Y-slangen) skylles grundigt med en 0,9 % natriumchlorid opløsning eller 5 % glucose opløsning før og efter Rapilysin injektionen.
In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % glucose solution prior to and following the Rapilysin injection.
Hos de patienter, hvor det samme i.v.-drop anvendes til at injicere andre lægemidler, skal i.v.-droppet skylles grundigt med en kendt forligelig opløsning både før og efter injektion med Dynastat.
In those patients where the same IV line is to be used to inject another medicinal product, the line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility.
Hos de patienter, hvor det samme i.v.-drop anvendes til at injicere andre lægemidler, skal i.v.-droppet skylles grundigt med en kendt forligelig opløsning både før og efter injektion med Dynastat.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Hos de patienter, hvor diarré førte til seponering, ophørte diarréen nogle få dage efter, at behandlingen var afbrudt.
In those patients in which diarrhoea led to discontinuation, it resolved after a few days of discontinuing treatment.
Hos de patienter, som alene indgik i forsøget på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA (RRR = 4,0 %, CI: -22,5 til 11,7 [p=0,639]).
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = - 4.0%; CI: -22.5 to 11.7 [p=0.639]).
Hos de patienter, som alene indgik i studiet på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA
Hos de patienter, som alene indgik i studiet på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA (RRR = 4,0
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =
Hos de patienter, som alene indgik i studiet på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA (RRR = 4,0 %, CI: -22,5 til 11,7 [p=0,639]).
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = - 4.0%; CI: -22.5 to 11.7 [p=0.639]).
Hos de patienter, som forblev i samme Simponi-behandling, som de var randomiseret til fra studiestart, blev DAS28-respons opretholdt til og med uge 104.
Among patients who remained on the Simponi treatment to which they were randomised at study start, DAS28 and HAQ DI responses were maintained through week 104.
Hos de patienter, som har utilstrækkelig initialt respons, er yderligere respons efter dette tidspunkt er usandsynligt.
In patients with inadequate initial response, additional response after this time is unlikely.
Hos de patienter, som tog Inovelon, blev der påvist et fald på 35,8 % i det samlede antal anfald, fra et gennemsnit på 290 anfald, i de 4 uger før behandlingen med Inovelon blev påbegyndt.
Patients taking Inovelon had a 35.8% reduction in the total number of seizures, falling from an average of 290 seizures in the four- week period before Inovelon was started.
Hos de patienter, som var evaluerbare for PD-L1- ekspression (98%), var 82% PD-L1-positive, og 18% var PD-L1-negative.
Among patients who were evaluable for PD-L1 expression (98%), 82% were PD-L1 positive and 18% were PD-L1 negative.
Hos de personer, der fik den anden vaccine 3 uger til 5 år efter vaccinationen med Pandemisk influenzavaccine H5N1 MedImmune, steg antistofferne med en faktor 4 hos 73 % (8 ud af 11), idet dette kun var tilfældet hos 10 % af de personer, der ikke tidligere var vaccineret med Pandemisk influenzavaccine H5N1 MedImmune.
In those who received the second vaccine 3 weeks to 5 years after vaccination with Pandemic influenza vaccine H5N1 MedImmune, antibodies increased 4-fold in 73% (8 out of 11) of the individuals compared with 10% of the individuals who had not been previously vaccinated with Pandemic influenza vaccine H5N1 MedImmune.
Hos de pædiatriske patienter <7 år blev 0/7 mandlige patienter testet positive for IgG-anti- agalsidase-alfa-antistoffer.
In paediatric patients <7 yrs of age, 0/7 male patients tested positive for IgG anti-agalsidase alfa antibodies.
Hos de resterende
In the remaining 55% of patients with unknown
Hos de resterende forsøgspersoner, der fik SIRTURO, var dødsårsagerne alkoholforgiftning, hepatitis/levercirrose, septisk shock/peritonitis, cerebrovakulær hændelse og ulykke med motorkøretøj..
The causes of death in the remaining SIRTURO subjects were alcohol poisoning, hepatitis/hepatic cirrhosis, septic shock/peritonitis, cerebrovascular accident and motor vehicle accident.